These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37659288)

  • 1. Efficacy of denosumab on bone metabolism and bone mineral density in renal transplant recipients: A systematic review and meta-analysis.
    Zhu P; Yang T; Le J; Fu X; Zhang L
    Transplant Rev (Orlando); 2023 Dec; 37(4):100793. PubMed ID: 37659288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of denosumab on bone metabolism and bone mineral density in kidney transplant patients: a systematic review and meta-analysis.
    Thongprayoon C; Acharya P; Aeddula NR; Torres-Ortiz A; Bathini T; Sharma K; Ungprasert P; Watthanasuntorn K; Suarez MLG; Salim SA; Kaewput W; Chenbhanich J; Mao MA; Cheungpasitporn W
    Arch Osteoporos; 2019 Mar; 14(1):35. PubMed ID: 30852679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies.
    Thongprayoon C; Acharya P; Acharya C; Chenbhanich J; Bathini T; Boonpheng B; Sharma K; Wijarnpreecha K; Ungprasert P; Gonzalez Suarez ML; Cheungpasitporn W
    Osteoporos Int; 2018 Aug; 29(8):1737-1745. PubMed ID: 29713798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.
    Hara T; Hijikata Y; Matsubara Y; Watanabe N
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013424. PubMed ID: 34231877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Follow-Up of Bone Mineral Density Changes in de novo Kidney Transplant Recipients Treated with Two Doses of the Receptor Activator of Nuclear Factor κB Ligand Inhibitor Denosumab.
    Kobel C; Frey D; Graf N; Wüthrich RP; Bonani M
    Kidney Blood Press Res; 2019; 44(5):1285-1293. PubMed ID: 31614356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship Between Bone Mineral Density and Risk of Vertebral Fractures with Denosumab Treatment in Japanese Postmenopausal Women and Men with Osteoporosis.
    Okubo N; Matsui S; Matsumoto T; Sugimoto T; Hosoi T; Osakabe T; Watanabe K; Takami H; Shiraki M; Nakamura T
    Calcif Tissue Int; 2020 Dec; 107(6):559-566. PubMed ID: 32839843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Twice-Yearly Denosumab on Prevention of Bone Mineral Density Loss in De Novo Kidney Transplant Recipients: A Randomized Controlled Trial.
    Bonani M; Frey D; Brockmann J; Fehr T; Mueller TF; Saleh L; von Eckardstein A; Graf N; Wüthrich RP
    Am J Transplant; 2016 Jun; 16(6):1882-91. PubMed ID: 26713403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of denosumab on bone mineral density and bone metabolism in patients with end-stage renal disease: A systematic review and meta-analysis.
    Gu Z; Yang X; Wang Y; Gao J
    Hemodial Int; 2023 Oct; 27(4):352-363. PubMed ID: 37264758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the clinical effectiveness and safety between the use of denosumab vs bisphosphonates in renal transplant patients.
    McKee H; Ioannidis G; Lau A; Treleaven D; Gangji A; Ribic C; Wong-Pack M; Papaioannou A; Adachi JD
    Osteoporos Int; 2020 May; 31(5):973-980. PubMed ID: 31900542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of denosumab on trabecular bone score in de novo kidney transplant recipients.
    Bonani M; Frey D; Graf N; Wüthrich RP
    Nephrol Dial Transplant; 2019 Oct; 34(10):1773-1780. PubMed ID: 30932161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
    Bone HG; Wagman RB; Brandi ML; Brown JP; Chapurlat R; Cummings SR; Czerwiński E; Fahrleitner-Pammer A; Kendler DL; Lippuner K; Reginster JY; Roux C; Malouf J; Bradley MN; Daizadeh NS; Wang A; Dakin P; Pannacciulli N; Dempster DW; Papapoulos S
    Lancet Diabetes Endocrinol; 2017 Jul; 5(7):513-523. PubMed ID: 28546097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive Power of Bone Turnover Biomarkers to Estimate Bone Mineral Density after Kidney Transplantation with or without Denosumab: A post hoc Analysis of the POSTOP Study.
    Heimgartner N; Graf N; Frey D; Saleh L; Wüthrich RP; Bonani M
    Kidney Blood Press Res; 2020; 45(5):758-767. PubMed ID: 32998144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the efficacy and tolerability of alendronate versus denosumab in kidney transplant patients with reduced bone mineral density.
    Sayed SA; El Wakeel LM; Elseasi AM; Shawki MA
    Pharmacotherapy; 2023 Sep; 43(9):904-912. PubMed ID: 37323099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis.
    Wu J; Zhang Q; Yan G; Jin X
    J Orthop Surg Res; 2018 Aug; 13(1):194. PubMed ID: 30071889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of denosumab on hypercalcemia and bone mineral density loss in kidney transplant recipients
.
    Nanmoku K; Shinzato T; Kubo T; Shimizu T; Yagisawa T
    Clin Nephrol; 2019 Jul; 92(1):1-8. PubMed ID: 30990412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates for prevention of osteopenia in kidney-transplant recipients: a systematic review of randomized controlled trials.
    Wang J; Yao M; Xu JH; Shu B; Wang YJ; Cui XJ
    Osteoporos Int; 2016 May; 27(5):1683-90. PubMed ID: 26733377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis.
    Beaudoin C; Jean S; Bessette L; Ste-Marie LG; Moore L; Brown JP
    Osteoporos Int; 2016 Sep; 27(9):2835-2844. PubMed ID: 27120345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of medications for osteoporosis in kidney transplant recipients or patients with chronic kidney disease: A meta-analysis.
    Leng Y; Yu X; Yang Y; Xia Y
    J Investig Med; 2023 Oct; 71(7):760-772. PubMed ID: 37387531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Denosumab in Postmenopausal Women With Osteoporosis: A Meta-Analysis.
    Gu HF; Gu LJ; Wu Y; Zhao XH; Zhang Q; Xu ZR; Yang YM
    Medicine (Baltimore); 2015 Nov; 94(44):e1674. PubMed ID: 26554766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Bone Mineral Density Changes in Kidney Transplant Recipients Treated with Denosumab: A Retrospective Study with Nonequivalent Control Group.
    Fassio A; Andreola S; Gatti D; Pollastri F; Gatti M; Fabbrini P; Gambaro G; Ferraro PM; Caletti C; Rossini M; Viapiana O; Bixio R; Adami G
    Calcif Tissue Int; 2024 Jul; 115(1):23-30. PubMed ID: 38730099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.